All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The randomized, open-label, parallel assignment phase III COLUMBA (MMY3012) study (NCT03277105) investigated the impact of either subcutaneous (SC) or intravenous (IV) administration of daratumumab (Darzalex®) on response rates in patients with relapsed/refractory multiple myeloma (RRMM).
The study found that daratumumab, co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), administered subcutaneously is non-inferior to IV administration.
No additional safety concerns were raised. The pharmaceutical company expected to present the data at an upcoming medical conference, publish in a peer-reviewed journal, and consider a regulatory submission for this formulation.
Providing daratumumab subcutaneously may result in a benefit to patients owing to the quicker and more convenient method of administration.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox